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Background: The prevalence of degenerative Aortic Stenosis (AS) is strongly linked to
the phenomenon of population aging. While elderly patients form the majority of patients
treated with AS, comorbidities place them at high for surgical aortic valve replacement
(SAVR). With the new treatment option of transcatheter aortic valve implantation
(TAVI), also patients formerly deemed inoperable can now be treated. Robust estimates
in an elderly population remain unclear. The objective of this study is to perform a
systematic review (SR) and meta-analysis (MA) to identify observational population-
based studies that report prevalence of severe AS in persons  70yrs.
Methods: A search of the published literature was conducted in Feb 2012 using Medical
databases. General population observational studies, surveys, registries that reported the
prevalence of degenerative severe AS in elderly persons (70yrs) were included.
Although the methods used to diagnose severe AS differed slightly between studies, the
cut-off diagnostic criteria used in this analysis, where severe AS is defined as aortic valve
area1 cm2, was taken from the ESC AS guidelines. A MA of prevalence estimates was
conducted in order to provide a point estimate (with confidence interval) of severe AS
prevalence. Heterogeneity was quantified using the I2 measure and its significance was
tested with the Q test.
Results: A total of 1524 citations were retrieved for review and 7 observational studies
reported severe AS in an elderly population. Five studies reported severe AS separately
(from other forms of AS) and were included in the MA. The pooled prevalence of severe
AS in persons 75yrs was 4.3% (95% CI 3.1%, 5.5%; heterogeneity, I252.8%,
chi-square p-value0.095). In persons 80yrs the pooled prevalence of severe AS was
4.8% (95% CI 3.4%, 6.3%; heterogeneity, I248.2%, chi-square p-value0.122). Due to
the moderate amount of heterogeneity in the estimates, which was deemed statistically
non-significant, a fixed-effect approach was used.
Conclusions: Our unique SR shows a prevalence of almost 5% in the octogenarians have
severe AS. These figures reconfirm AS as a major disease and form a starting point in light
of new less invasive TAV implantation.
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Background: Transcatheter Aortic Valve Implantation (TAVI) offers an alternative
treatment option in patients who are not eligible for surgical aortic valve replacement
(SAVR). In this patient group TAVI has been demonstrated to improve survival and
Health Related Quality of life. Cost-effectiveness analysis compares the costs and clinical
outcomes of an intervention in order to evaluate the extent to which it provides value for
money. Cost-effectiveness thresholds, representing the maximum amount societies are
willing to pay for a unit of additional benefit (typically expressed as Quality Adjusted Life
Years – QALYs), are used in the assessment of health technologies. This review compares
published cost-effectiveness studies performed on TAVI vs. medical management (MM)
in patients ineligible for SAVR.
Methods: The Medline database was systematically searched and health technology
assessment (HTA) reports were analyzed in order to retrieve published cost-effectiveness
models. An internationally accepted checklist was used to assess all aspects of each model
and to illustrate similarities or differences.
Results: Three cost-effectiveness models were identified. The first publication appeared
in Heart in November 2011 (Watt et al). More recently, in 2012, another two
cost-effectiveness analyses of TAVI were published: Neyt et al in BMJ Open and
Reynolds et al in Circulation. The perspectives of three different country healthcare
systems are therefore represented: UK, Belgium and US, respectively. Main results are
shown in the table below:
Watt et al Reynolds et al Neyt et al
Currency GBP US (USD) Euro’s
Perspective National Health
Service
US Healthcare
System
(modified
societal)
Belgian
Healthcare
Payer
Time horizon Lifetime horizon Lifetime
horizon
3 years
Modelling
approach
Markov Trial based
evaluation with
extrapolation
Markov
Discount rate
(Costs)
3.5% p.a. 3% p.a. 3%.p.a.
Discount rate
(Benefits)
3.5% p.a. 3% p.a. 1.5% p.a.
Incremental Cost £25,300 $79,837 €33,200
Incremental effect
(QALY)
1.50 1.3 0.74
ICER (original) £16,700 $61,889 €44,900
ICER (USD)
(converted using
OECD PPP 2010)
$25,340 $61,889 $51,950
Conclusions: Cost effectiveness evaluations on TAVI in the treatment of patients
ineligible for SAVR have been reported in three different countries. In those countries,
thresholds, discount rates, medical costs, modeling approach and health care systems are
different. Despite these differences, the published analyses show that TAVI is a
cost-effective treatment when compared to optimal MM in patients unsuitable for SAVR
replacement.
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Background: TAVI has been introduced to offer a new treatment option in patients who
are not eligible for surgical AVR and it has been demonstrated to improve survival and
Health Related Quality of life. In Europe just over 18000 procedures were performed in
2011. This figure is set to grow depending on the epidemiology of the disease, the
demographics of the population, clinical trials advancement as well as regulatory and
reimbursement approvals. Significant differences in TAVI rates continue to exist within
Europe in 2011 due to different country healthcare systems.
Methods: A qualitative market survey was piloted amongst a group of 65 implanting centers
from 9 European countries. The aim is to assess their perception on what the main barriers in
addressing disparities in accessing TAVI across Europe are. Telephone interviews were
conducted with cardio-thoracic centers based on pre-arranged questionnaires.
Results: Based on the reported TAVI implant rate per million inhabitants, 86% of the
interviewees think that the medical need of treating patients with severe symptomatic
aortic stenosis ineligible for conventional surgery is still unmet. In 2011 these centers
assessed 5770 patients with severe symptomatic AS. 2120 (36.7%) were considered at
high risk for surgical AVR and indicated for TAVI. Only 1211 patients (55%) received
TAVI, 276 (12%) were treated with Balloon Aortic Valvuloplasty, 399 (18.1%) received
treatments with drugs only, and 314 (14.2%) were managed using other medical
management approaches. The decision to not refer 45% of the patients with severe
symptomatic aortic stenosis to TAVI was based upon different reasons (such as budget
constraints, national reimbursement issues, hospital capacity, clinical assessment).
Conclusions: This first pilot survey suggests that, despite TAVI being accepted as
standard of care for patients suffering from severe AS, other inter-related reasons, such as
budgetary constraints and patient’s health expectancy hamper the drive for a wider TAVI
adoption. Financial limits like budget constraints and hospital capacity represent more
than 60% of reasons for denying a patient to be treated with TAVI.
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